Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Trial Profile

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Portal hypertension; Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms ANGEL; Portopulm
  • Most Recent Events

    • 24 May 2017 Primary endpoint (6 minute walk distance (6MWD)) has not been met as per the results presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Primary endpoint (Pulmonary vascular resistance (PVR)) has been met as per the results presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top